After going through two Cancer Disease Deliberation Committee meetings and two Drug Reimbursement Evaluation Committee meetings, the anticancer drug ‘Enhertu’ has finally started drug pricing negotiations with the National Health Insurance Service.

As the drug has passed drug evaluations after repeated revisions, the negotiations are expected to go smoothly. In particular, it will be interesting to see if the government grants reimbursement within April, as there are analysts who believe that the government is using the scenario of coverage before the parliamentary election.

According to the industry on the 28th, the Health and Welfare Ministry recently issued a drug pricing negotiati